- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
- Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
- Stoke Therapeutics Announces Proposed Public Offering
- Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.53 |
---|---|
High | 15.64 |
Low | 14.60 |
Bid | 14.40 |
Offer | 15.65 |
Previous close | 15.81 |
Average volume | 806.58k |
---|---|
Shares outstanding | 52.12m |
Free float | 49.70m |
P/E (TTM) | -- |
Market cap | 824.02m USD |
EPS (TTM) | -2.42 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼